LymphedemaV1, PubMed, Checkpoint, bibRecord, 001292

Recurrent erysipelas--risk factors and clinical presentation.

Identifieur interne : 001292 ( PubMed/Checkpoint ); précédent : 001291; suivant : 001293

Recurrent erysipelas--risk factors and clinical presentation.

Auteurs : Malin Inghammar [Suède] ; Magnus Rasmussen ; Adam Linder

Source :

BMC infectious diseases [ 1471-2334 ] ; 2014.

RBID : pubmed:24884840

Descripteurs français

KwdFr :
- Adolescent, Adulte, Adulte d'âge moyen, Antibactériens (usage thérapeutique), Facteurs de risque, Femelle, Humains, Jeune adulte, Maladies transmissibles (traitement médicamenteux), Maladies transmissibles (épidémiologie), Mâle, Récidive, Sujet âgé, Sujet âgé de 80 ans ou plus, Suède (épidémiologie), Érysipèle (traitement médicamenteux), Érysipèle (épidémiologie), Études transversales.
MESH :
- traitement médicamenteux : Maladies transmissibles, Érysipèle.
- usage thérapeutique : Antibactériens.
- épidémiologie : Maladies transmissibles, Suède, Érysipèle.
- Adolescent, Adulte, Adulte d'âge moyen, Facteurs de risque, Femelle, Humains, Jeune adulte, Mâle, Récidive, Sujet âgé, Sujet âgé de 80 ans ou plus, Études transversales.
Wicri :
- geographic : Suède.

English descriptors

KwdEn :
- Adolescent, Adult, Aged, Aged, 80 and over, Anti-Bacterial Agents (therapeutic use), Communicable Diseases (drug therapy), Communicable Diseases (epidemiology), Cross-Sectional Studies, Erysipelas (drug therapy), Erysipelas (epidemiology), Female, Humans, Male, Middle Aged, Recurrence, Risk Factors, Sweden (epidemiology), Young Adult.
MESH :
- chemical , therapeutic use : Anti-Bacterial Agents.
- geographic , epidemiology : Sweden.
- drug therapy : Communicable Diseases, Erysipelas.
- epidemiology : Communicable Diseases, Erysipelas.
- Adolescent, Adult, Aged, Aged, 80 and over, Cross-Sectional Studies, Female, Humans, Male, Middle Aged, Recurrence, Risk Factors, Young Adult.

Abstract

Erysipelas is a common infection that often recurs, but the impact of specific risk factors for reoccurrence remains elusive. In the present study we aimed at clarifying predisposing conditions for reoccurrence.

DOI: 10.1186/1471-2334-14-270
PubMed: 24884840

Affiliations:

Suède

Links toward previous steps (curation, corpus...)

to stream PubMed, to step Corpus: 001500
to stream PubMed, to step Curation: 001500

Links to Exploration step

pubmed:24884840

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Recurrent erysipelas--risk factors and clinical presentation.</title>
<author><name sortKey="Inghammar, Malin" sort="Inghammar, Malin" uniqKey="Inghammar M" first="Malin" last="Inghammar">Malin Inghammar</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Clinical Sciences, Division of Infection Medicine, Klinikgatan 1, Skåne University Hospital, Lund, Lund SE-221 85, Sweden. malin.inghammar@med.lu.se.</nlm:affiliation>
<country xml:lang="fr">Suède</country>
<wicri:regionArea>Department of Clinical Sciences, Division of Infection Medicine, Klinikgatan 1, Skåne University Hospital, Lund, Lund SE-221 85</wicri:regionArea>
<wicri:noRegion>Lund SE-221 85</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Rasmussen, Magnus" sort="Rasmussen, Magnus" uniqKey="Rasmussen M" first="Magnus" last="Rasmussen">Magnus Rasmussen</name>
</author>
<author><name sortKey="Linder, Adam" sort="Linder, Adam" uniqKey="Linder A" first="Adam" last="Linder">Adam Linder</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2014">2014</date>
<idno type="RBID">pubmed:24884840</idno>
<idno type="pmid">24884840</idno>
<idno type="doi">10.1186/1471-2334-14-270</idno>
<idno type="wicri:Area/PubMed/Corpus">001500</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001500</idno>
<idno type="wicri:Area/PubMed/Curation">001500</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001500</idno>
<idno type="wicri:Area/PubMed/Checkpoint">001500</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">001500</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Recurrent erysipelas--risk factors and clinical presentation.</title>
<author><name sortKey="Inghammar, Malin" sort="Inghammar, Malin" uniqKey="Inghammar M" first="Malin" last="Inghammar">Malin Inghammar</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Clinical Sciences, Division of Infection Medicine, Klinikgatan 1, Skåne University Hospital, Lund, Lund SE-221 85, Sweden. malin.inghammar@med.lu.se.</nlm:affiliation>
<country xml:lang="fr">Suède</country>
<wicri:regionArea>Department of Clinical Sciences, Division of Infection Medicine, Klinikgatan 1, Skåne University Hospital, Lund, Lund SE-221 85</wicri:regionArea>
<wicri:noRegion>Lund SE-221 85</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Rasmussen, Magnus" sort="Rasmussen, Magnus" uniqKey="Rasmussen M" first="Magnus" last="Rasmussen">Magnus Rasmussen</name>
</author>
<author><name sortKey="Linder, Adam" sort="Linder, Adam" uniqKey="Linder A" first="Adam" last="Linder">Adam Linder</name>
</author>
</analytic>
<series><title level="j">BMC infectious diseases</title>
<idno type="eISSN">1471-2334</idno>
<imprint><date when="2014" type="published">2014</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adolescent</term>
<term>Adult</term>
<term>Aged</term>
<term>Aged, 80 and over</term>
<term>Anti-Bacterial Agents (therapeutic use)</term>
<term>Communicable Diseases (drug therapy)</term>
<term>Communicable Diseases (epidemiology)</term>
<term>Cross-Sectional Studies</term>
<term>Erysipelas (drug therapy)</term>
<term>Erysipelas (epidemiology)</term>
<term>Female</term>
<term>Humans</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Recurrence</term>
<term>Risk Factors</term>
<term>Sweden (epidemiology)</term>
<term>Young Adult</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Adolescent</term>
<term>Adulte</term>
<term>Adulte d'âge moyen</term>
<term>Antibactériens (usage thérapeutique)</term>
<term>Facteurs de risque</term>
<term>Femelle</term>
<term>Humains</term>
<term>Jeune adulte</term>
<term>Maladies transmissibles (traitement médicamenteux)</term>
<term>Maladies transmissibles (épidémiologie)</term>
<term>Mâle</term>
<term>Récidive</term>
<term>Sujet âgé</term>
<term>Sujet âgé de 80 ans ou plus</term>
<term>Suède (épidémiologie)</term>
<term>Érysipèle (traitement médicamenteux)</term>
<term>Érysipèle (épidémiologie)</term>
<term>Études transversales</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Anti-Bacterial Agents</term>
</keywords>
<keywords scheme="MESH" type="geographic" qualifier="epidemiology" xml:lang="en"><term>Sweden</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Communicable Diseases</term>
<term>Erysipelas</term>
</keywords>
<keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Communicable Diseases</term>
<term>Erysipelas</term>
</keywords>
<keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Maladies transmissibles</term>
<term>Érysipèle</term>
</keywords>
<keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Antibactériens</term>
</keywords>
<keywords scheme="MESH" qualifier="épidémiologie" xml:lang="fr"><term>Maladies transmissibles</term>
<term>Suède</term>
<term>Érysipèle</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Adolescent</term>
<term>Adult</term>
<term>Aged</term>
<term>Aged, 80 and over</term>
<term>Cross-Sectional Studies</term>
<term>Female</term>
<term>Humans</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Recurrence</term>
<term>Risk Factors</term>
<term>Young Adult</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Adolescent</term>
<term>Adulte</term>
<term>Adulte d'âge moyen</term>
<term>Facteurs de risque</term>
<term>Femelle</term>
<term>Humains</term>
<term>Jeune adulte</term>
<term>Mâle</term>
<term>Récidive</term>
<term>Sujet âgé</term>
<term>Sujet âgé de 80 ans ou plus</term>
<term>Études transversales</term>
</keywords>
<keywords scheme="Wicri" type="geographic" xml:lang="fr"><term>Suède</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Erysipelas is a common infection that often recurs, but the impact of specific risk factors for reoccurrence remains elusive. In the present study we aimed at clarifying predisposing conditions for reoccurrence.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">24884840</PMID>
<DateCreated><Year>2014</Year>
<Month>06</Month>
<Day>04</Day>
</DateCreated>
<DateCompleted><Year>2014</Year>
<Month>12</Month>
<Day>30</Day>
</DateCompleted>
<DateRevised><Year>2017</Year>
<Month>02</Month>
<Day>20</Day>
</DateRevised>
<Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1471-2334</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>14</Volume>
<PubDate><Year>2014</Year>
<Month>May</Month>
<Day>18</Day>
</PubDate>
</JournalIssue>
<Title>BMC infectious diseases</Title>
<ISOAbbreviation>BMC Infect. Dis.</ISOAbbreviation>
</Journal>
<ArticleTitle>Recurrent erysipelas--risk factors and clinical presentation.</ArticleTitle>
<Pagination><MedlinePgn>270</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1186/1471-2334-14-270</ELocationID>
<Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Erysipelas is a common infection that often recurs, but the impact of specific risk factors for reoccurrence remains elusive. In the present study we aimed at clarifying predisposing conditions for reoccurrence.</AbstractText>
<AbstractText Label="METHODS" NlmCategory="METHODS">Medical records were reviewed from all patients ≥18 years of age diagnosed with erysipelas at the Department of Infectious Diseases at Skåne University Hospital, Sweden, from January 2007 to February 2011. 502 patients were included, of which 357 were single episode erysipelas and 145 had recurrent erysipelas. These two groups were compared regarding underlying conditions and clinical presentation.</AbstractText>
<AbstractText Label="RESULTS" NlmCategory="RESULTS">Erysipelas in the lower limbs had the greatest propensity of recurrence. The associations between underlying conditions and recurrence were largely depending on the site of erysipelas. Overall, the most prominent risk factor for recurrence was lymphedema and other conditions causing a chronic impairment of the defence against microbes. Conditions temporarily disrupting the skin barrier (e.g. a local wound or toe web intertrigo), although likely being risk factors for erysipelas per se, did not seem to predispose to repeated episodes. Individuals with recurrent erysipelas tended to seek medical attention earlier, and were less likely to be hospitalized or receive intravenous antibiotics, but there was no evidence of any difference in inflammatory reaction when taking confounding factors into account.</AbstractText>
<AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">In this large cross-sectional study of over 500 patients with erysipelas, lymphedema was the most prominent risk factors for recurrence although the distribution of predisposing conditions varies depending on the site of erysipelas.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Inghammar</LastName>
<ForeName>Malin</ForeName>
<Initials>M</Initials>
<AffiliationInfo><Affiliation>Department of Clinical Sciences, Division of Infection Medicine, Klinikgatan 1, Skåne University Hospital, Lund, Lund SE-221 85, Sweden. malin.inghammar@med.lu.se.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Rasmussen</LastName>
<ForeName>Magnus</ForeName>
<Initials>M</Initials>
</Author>
<Author ValidYN="Y"><LastName>Linder</LastName>
<ForeName>Adam</ForeName>
<Initials>A</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic"><Year>2014</Year>
<Month>05</Month>
<Day>18</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo><Country>England</Country>
<MedlineTA>BMC Infect Dis</MedlineTA>
<NlmUniqueID>100968551</NlmUniqueID>
<ISSNLinking>1471-2334</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000900">Anti-Bacterial Agents</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<CommentsCorrectionsList><CommentsCorrections RefType="Cites"><RefSource>Clin Infect Dis. 2008 Mar 15;46(6):855-61</RefSource>
<PMID Version="1">18260753</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Infection. 1987 Mar-Apr;15(2):105-6</RefSource>
<PMID Version="1">3110071</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Scand J Infect Dis. 1986;18(6):519-24</RefSource>
<PMID Version="1">3810046</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Clin Infect Dis. 1996 Nov;23(5):1091-8</RefSource>
<PMID Version="1">8922808</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>BMJ. 2009;338:b2393</RefSource>
<PMID Version="1">19564179</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Am J Med. 1992 Nov;93(5):543-8</RefSource>
<PMID Version="1">1364813</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Dermatology. 2004;209(4):301-7</RefSource>
<PMID Version="1">15539893</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Dermatology. 2007;215(2):118-22</RefSource>
<PMID Version="1">17684373</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Eur Acad Dermatol Venereol. 2006 Aug;20(7):834-9</RefSource>
<PMID Version="1">16898907</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Clin Microbiol Infect. 2010 Jun;16(6):729-34</RefSource>
<PMID Version="1">19694769</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Br J Dermatol. 2006 Nov;155(5):947-50</RefSource>
<PMID Version="1">17034523</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Surg Annu. 1982;14:73-83</RefSource>
<PMID Version="1">7179061</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Radiother Oncol. 2010 Nov;97(2):281-7</RefSource>
<PMID Version="1">20970212</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Eur J Intern Med. 2004 Nov;15(7):446-450</RefSource>
<PMID Version="1">15581749</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Dtsch Dermatol Ges. 2004 Feb;2(2):89-95</RefSource>
<PMID Version="1">16279242</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Int J Dermatol. 1990 Sep;29(7):459-67</RefSource>
<PMID Version="1">2228369</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Am J Clin Dermatol. 2003;4(3):157-63</RefSource>
<PMID Version="1">12627991</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Dermatology. 2007;214(1):52-7</RefSource>
<PMID Version="1">17191048</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Arch Dermatol. 1989 Jun;125(6):779-82</RefSource>
<PMID Version="1">2658843</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Am J Med Sci. 2006 Dec;332(6):304-7</RefSource>
<PMID Version="1">17170620</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Am J Epidemiol. 2009 May 1;169(9):1133-9</RefSource>
<PMID Version="1">19318618</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>N Engl J Med. 1996 Jan 25;334(4):240-5</RefSource>
<PMID Version="1">8532002</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>BMJ. 1999 Jun 12;318(7198):1591-4</RefSource>
<PMID Version="1">10364117</PMID>
</CommentsCorrections>
</CommentsCorrectionsList>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000900" MajorTopicYN="N">Anti-Bacterial Agents</DescriptorName>
<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D003141" MajorTopicYN="N">Communicable Diseases</DescriptorName>
<QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
<QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D003430" MajorTopicYN="N">Cross-Sectional Studies</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D004886" MajorTopicYN="N">Erysipelas</DescriptorName>
<QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
<QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D012008" MajorTopicYN="N">Recurrence</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D013548" MajorTopicYN="N" Type="Geographic">Sweden</DescriptorName>
<QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName>
</MeshHeading>
</MeshHeadingList>
<OtherID Source="NLM">PMC4033615</OtherID>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="received"><Year>2013</Year>
<Month>11</Month>
<Day>11</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="accepted"><Year>2014</Year>
<Month>05</Month>
<Day>13</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2014</Year>
<Month>6</Month>
<Day>3</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2014</Year>
<Month>6</Month>
<Day>3</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2014</Year>
<Month>12</Month>
<Day>31</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>epublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">24884840</ArticleId>
<ArticleId IdType="pii">1471-2334-14-270</ArticleId>
<ArticleId IdType="doi">10.1186/1471-2334-14-270</ArticleId>
<ArticleId IdType="pmc">PMC4033615</ArticleId>
</ArticleIdList>
</PubmedData>
</pubmed>
<affiliations><list><country><li>Suède</li>
</country>
</list>
<tree><noCountry><name sortKey="Linder, Adam" sort="Linder, Adam" uniqKey="Linder A" first="Adam" last="Linder">Adam Linder</name>
<name sortKey="Rasmussen, Magnus" sort="Rasmussen, Magnus" uniqKey="Rasmussen M" first="Magnus" last="Rasmussen">Magnus Rasmussen</name>
</noCountry>
<country name="Suède"><noRegion><name sortKey="Inghammar, Malin" sort="Inghammar, Malin" uniqKey="Inghammar M" first="Malin" last="Inghammar">Malin Inghammar</name>
</noRegion>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/LymphedemaV1/Data/PubMed/Checkpoint

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001292 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd -nk 001292 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Sante
   |area=    LymphedemaV1
   |flux=    PubMed
   |étape=   Checkpoint
   |type=    RBID
   |clé=     pubmed:24884840
   |texte=   Recurrent erysipelas--risk factors and clinical presentation.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/RBID.i   -Sk "pubmed:24884840" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd   \
       | NlmPubMed2Wicri -a LymphedemaV1

This area was generated with Dilib version V0.6.31.
Data generation: Sat Nov 4 17:40:35 2017. Site generation: Tue Feb 13 16:42:16 2024

	Serveur d'exploration sur le lymphœdème
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration sur le lymphœdème

Recurrent erysipelas--risk factors and clinical presentation.

Recurrent erysipelas--risk factors and clinical presentation.

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki